newsfilter
← Latest News
PR Newswire·

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the ...